JERSEY
CITY, N.J., June 21,
2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd.
announces the release of a market assessment report on the
"Targeted Protein Degradation Market"- Distribution by Type of
Degrader (SERD, PROTAC and Molecular Glue), Target Indication
(Breast Cancer and Multiple Myeloma), Industry Trends, and Global
Forecasts, 2024-2031 And Segment Revenue and Forecast To
2031."
The Targeted Protein Degradation Market is estimated to
reach over USD 2.65 Bn by
2031, exhibiting a CAGR of 26.3% during the forecast
period.
Targeted protein degradation (TPD) seeks to completely remove
specific proteins from the cell, rather than merely inhibiting
their activity. This approach can potentially provide more
effective and sustained treatment outcomes for various diseases by
thoroughly eliminating disease-causing proteins. By leveraging the
cell's natural degradation pathways, TPD can address issues that
traditional therapies cannot, such as drug resistance and
incomplete inhibition. Consequently, this innovative strategy holds
significant promise for advancing the treatment of conditions like
cancer, neurodegenerative diseases, and infectious diseases,
offering new hope for patients with previously intractable
conditions.
Targeted protein degradation (TPD) seeks to completely remove
specific proteins from the cell, rather than merely inhibiting
their activity. This approach can potentially provide more
effective and sustained treatment outcomes for various diseases by
thoroughly eliminating disease-causing proteins. By leveraging the
cell's natural degradation pathways, TPD can address issues that
traditional therapies cannot, such as drug resistance and
incomplete inhibition. Improved techniques in drug delivery,
high-throughput screening, and protein engineering are enhancing
the efficacy and specificity of TPD therapies.
Download Free Sample and ToC of the Report:
https://www.insightaceanalytic.com/request-sample/2530
List of Prominent Players in the Targeted Protein
Degradation Market:
- Arvinas
- Bristol-Myers Squibb
- C4 Therapeutics
- Loxo Oncology
- Olema Oncology
- Radius Health
- AstraZeneca
- Roche
- BeiGene
- InnoCare Pharma
- Kangpu Biopharmaceuticals
- Kintor Pharmaceuticals
- Medivir
- Monte Rosa Therapeutics
- Ranok Therapeutics
- Sanofi
- Zentalis Pharmaceuticals
- Eisai Therapeutics
Targeted Protein Degradation Market Report Scope:
Report
Attribute
|
Specifications
|
Market Size Value In
2023
|
USD 0.42 Bn
|
Revenue Forecast In
2031
|
USD 2.65 Bn
|
Growth Rate
CAGR
|
CAGR of 26.3% from 2024
to 2031
|
Quantitative
Units
|
Representation of
revenue in US$ Bn and CAGR from 2024 to 2031
|
Historic
Year
|
2019 to 2023
|
Forecast
Year
|
2024-2031
|
Report
Coverage
|
The forecast of
revenue, the position of the company, the competitive market
structure, growth prospects, and trends
|
Segments
Covered
|
By Distribution by Type
of Degrader, Target Indication
|
Regional
Scope
|
North America; Europe;
Asia Pacific; Latin America; Middle East & Africa
|
Country
Scope
|
U.S.; Canada; U.K.;
Germany; China; India; Japan; Brazil; Mexico; The UK; France;
Italy; Spain; China; Japan; India; South Korea; Southeast Asia;
South Korea; South East Asia
|
Order 180 Pages Full Report @
https://www.insightaceanalytic.com/buy-report/2530
Market Dynamics:
Drivers:
The promising potential of TPD to transform disease treatment is
attracting significant interest and investment from venture
capitalists and pharmaceutical companies. Positive outcomes from
ongoing research and clinical trials are boosting confidence in TPD
therapies, accelerating their development. Additionally,
partnerships between pharmaceutical companies, biotech firms, and
academic institutions are fostering innovation and expanding the
reach of TPD research and applications. The global increase in
diseases such as cancer and neurodegenerative disorders is creating
a demand for innovative therapies, making TPD a valuable
approach.
Challenges:
Developing PROTACs and other TPD molecules is technically
complex, requiring precise design to ensure efficacy and
selectivity. Potential off-target effects and toxicity are
significant concerns, necessitating thorough evaluation in
preclinical and clinical trials. Additionally, high research and
development costs, along with the need for extensive clinical
trials, can be prohibitive for some companies.
Regional Trends:
There's a growing focus on personalized medicine in North America, with an emphasis on developing
targeted therapies for specific patient populations. TPD aligns
well with this trend, offering the potential for more precise and
effective treatments. The region boasts a well-established and
well-funded pharmaceutical industry with a strong track record of
innovation in drug discovery. These companies have the resources
and expertise to invest heavily in TPD research and development,
propelling the market forward.
Curious about this latest version of the report? @
https://www.insightaceanalytic.com/enquiry-before-buying/2530
Recent Developments:
- In April 2024, Arvinas, Inc.,
announced that it has signed a strategic license agreement with
Novartis for the global development and commercialization of
ARV-766, Arvinas' second-generation PROTACĀ® androgen receptor (AR)
degrader for patients with prostate cancer. is a clinical-stage
biotechnology company developing a new class of drugs based on
targeted protein degradation. An asset purchase agreement for the
sale of Arvinas' preclinical AR-V7 program to Novartis is also a
part of the transaction.
- In September 2023, Bristol Myers
Squibb is hosting a Research and Development (R&D) Day in
New York to discuss the company's
R&D capabilities and strategy and provide information about its
strong pipeline that supports sustainable long-term growth. The
company's leadership team will also showcase its improved R&D
framework and unique research platforms, which are anticipated to
provide exceptional productivity that produces top-notch
early-stage candidates and noticeably shortens R&D
timelines.
Segmentation of Targeted Protein Degradation
Market.
By Type of Degrader
- SERD
- PROTAC
- Molecular Glue
By Target Indication
- Breast Cancer
- Multiple Myeloma
By Region
North America-
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and
Africa
For More Customization @
https://www.insightaceanalytic.com/customisation/2530
Why should buy this report:
- To receive a comprehensive analysis of the prospects for global
Targeted Protein Degradation market
- To receive industry overview and future trends of global
Targeted Protein Degradation market
- To analyze the Targeted Protein Degradation market drivers and
challenges
- To get information on the Targeted Protein Degradation market
size value (US$ Mn) forecast till 2031
- Major Investments, Mergers & Acquisition in global Targeted
Protein Degradation industry
Other Related Reports Published by InsightAce
Analytic:
SERD Therapeutics Market
Molecular Glue Degrader Market
Protein Design and Engineering Market
Check Our Satisfied Clients Portfolio @
https://www.insightaceanalytic.com/our-clients
About Us:
InsightAce Analytic is a market research and consulting firm
that enables clients to make strategic decisions. Our qualitative
and quantitative market intelligence solutions inform the need for
market and competitive intelligence to expand businesses. We help
clients gain competitive advantage by identifying untapped markets,
exploring new and competing technologies, segmenting potential
markets and repositioning products. Our expertise is in providing
syndicated and custom market intelligence reports with an in-depth
analysis with key market insights in a timely and cost-effective
manner.
Contact Us:
InsightAce Analytic PVT. LTD
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Follow us on LinkedIn:
https://www.linkedin.com/company/insightace-analytic-pvt-ltd/
Logo:
https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/targeted-protein-degradation-market-protac-segment-is-expected-to-highest-growth-rate-during-2024-2031--revealed-by-insightace-analytic-pvt-ltd-302178845.html
SOURCE InsightAce Analytic Pvt. Ltd